Search Results

Discovery on Target’s 19th Annual GPCR-Based Drug Discovery Targeting G Protein-Coupled Receptors for New Therapeutic September 2nd to 8th, 2024 Industry News Superluminal Medicines Closes $120 Million Series A Round Domain Therapeutics platform; Carterra Ultra™ ushers in a new frontier in fragment and small molecule drug discovery Is the pharma Heterodimer, TAS1R2/1R3 GPCRs in Neuroscience GPCR-Mediated Natural Products and Compounds: Potential Therapeutic

drug discovery; new strategies for inflammatory disease treatment; growth strategies from Tectonic Therapeutics Katerina Leftheris : New technologies overcoming peptide limitations with insights from both pharma and

treatment selection in patients with advanced haematological cancers, international partnerships with pharma

These nuances define therapeutic potential and side-effect risk. Each mode reshapes both potency and therapeutic window. Kenakin Content trusted by biotech, pharma, and academia 💎 $2999/year — one conference cost = a full

Industry News Inversago Pharma to Participate at the 2023 SVB Securities Global BioPharma Conference Orbit Discovery and Endevica Bio enter multi-target collaboration to advance development of cachexia therapeutics

potential use of Opn5 and its homologs Industry News The Leading GPCR Company in Immuno-Oncology, Domain Therapeutics Proof-of-Concept Studies Sosei Heptares’ President & CEO Chris Cargill Wins Executive of the Year at the Citeline Pharma

Stay tuned for our next symposium on GPCRs as Therapeutics Targets on October 11th, 2024. Post-COVID-Vaccination Syndrome With Anti-G-Protein-Coupled Receptor (GPCR) Antibodies Treated With Therapeutic neutrophil biology: inflammation, resolution and beyond Exploring GPCR signaling pathway networks as cancer therapeutic Crinetics Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Nxera Pharma

Separate effect size from time:  Use allosteric modulators to expand therapeutic index and reduce overdose topic suggestions 🆕 Weekly new releases to stay ahead of the science 🧠 Content built for biotech, pharma Why It Matters In the CNS, where receptor localization and real-time signaling shape therapeutic outcomes

When a drug outlives its exposure , toxic interactions can be just as persistent as therapeutic ones. Kenakin Content trusted by biotech, pharma, and academia 💎 $2999/year — one conference cost = a full

Non-canonical Golgi-compartmentalized Gβγ signaling: mechanisms, functions, and therapeutic targets. Announces First-in-Human Study for Bristol Myers Squibb In-Licensed PKC Theta Inhibitor, EXS4318 GPCR Therapeutics Multiple Myeloma Behind Friday's $161M IPO: A star scientist, GPCR drug discovery and a plan to challenge pharma interest’ Addex Strategic Partner Completes Enrollment In Adx71149 Epilepsy Phase 2 Study Part 1 Domain Therapeutics

Industry News Monash University retains its N° 2 global ranking for Pharmacy and Pharmacology Addex Therapeutics to Release Full-Year 2023 Financial Results and Host Conference Call on April 18, 2024 Nxera Pharma

GLP-1 drugs’ Opening Ceremony of Xuzhou Zhongshu Research Site and CNS Drug Innovation Forum Nxera Pharma

Xavier Leroy on his appointment as CEO of GIO Therapeutics! Congratulations to Domain Therapeutics for being awarded the RHU SPRINT consortium grant. Endocrinology, and Taste The Role of Gut Microbiota and Associated Compounds in Cardiovascular Health and its Therapeutic Living Cells with Cucurbit[7]uril and Hemicyanine as a "Turn-On" Fluorescence Probe Industry News Domain Therapeutics Xavier Leroy appointed as CEO of GIO Therapeutics GPCR Events, Meetings, and Webinars NOW!

Xavier Leroy for his new role as CEO of GIO Therapeutics Dr. Molecular mechanism of GPCR spatial organization at the plasma membrane Industry News Launch of GIO Therapeutics , founded by Cumulus Oncology, to develop therapeutics targeting G protein-coupled receptors to treat cancer and inflammation AVROBIO and Tectonic Therapeutic Announce Merger Trevena Inc Elevates Barry February 20, 2024 | Career Opportunities in Pharmacology and Drug Discovery March 13 - 15 | 9th German Pharm-Tox

KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders Inversago Pharma

for Drug Discovery While the Carlsson lab is rooted in academia, its impact extends into biotech and pharma

your topic suggestions Weekly new releases  to stay ahead of the science Content built for biotech, pharma

How do molecules make the leap from laboratory concept to therapeutic reality? miss the forest for the trees The critical importance of translation —turning lab data into meaningful therapeutic

to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Pharmacology GPCR Jobs GPCR Molecular Pharmacologist Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

and drug discovery in endocrinology and metabolism Reviews, GPCRs, and more Butyrate as a promising therapeutic cadherin G protein-coupled receptors that bind cry toxins of Bacillus thuringiensis Industry News Domain Therapeutics Research GPCR Events, Meetings, and Webinars March 13 - 15 | Biologics 2024 March 13 - 15 | 9th German Pharm-Tox

signaling, influencing a wide array of physiological processes and serving as critical targets for therapeutic significant findings that enhance our understanding of GPCRs' roles in immune function and potential therapeutic macrophages suggest that these GPCRs could be targeted to modulate inflammatory responses, offering potential therapeutic the field continues to evolve, the insights gained from this research will be instrumental in shaping therapeutic

2025 Milestones Recursion and Exscientia have merged to enhance drug discovery GPCR Classes Pathios Therapeutics to GPCR Drug Discovery March 12 - 14, 2025 | NextGen Biomed 2025 March 25 - 28, 2025 | 10th German Pharm-Tox Basic and Clinical Pharmacology GPCR Jobs NEW Scientist - Biology Scientist I Cell Biology - Tectonic Therapeutic

This foundational knowledge guides researchers in the development of new therapeutics. It can inform decisions in drug design, improving therapeutic outcomes and reducing unwanted side effects This understanding can enhance your appreciation for drug development and therapeutic action.

and the complexity of the central nervous system (CNS) pose a challenge for developing successful therapeutics Emerging GPCR Therapeutic Targets in CNS Drug Discovery GPCRs have been studied for decades, but there Of the traditional GPCRs, CBRs are gaining ground as potential therapeutic targets in several CNS diseases One of the best tools to study therapeutic targets are fluorescent ligands , which are very useful in G-Protein-Coupled Receptors in CNS: A Potential Therapeutic Target for Intervention in Neurodegenerative

Selection  – Master GPCR behavior beyond second messengers   Build sharper strategies for GPCR-targeted therapeutics receptor biology—and how they’re being used to de-orphanize GPCRs, explore autoantibodies, and uncover new therapeutic

mGluR2, and a big headline, Novo Nordisk’s $2.2B deal with Septerna to develop GPCR-targeted obesity therapeutics Biased signalling of Class B G protein-coupled receptor-targeted therapeutics .  

Our partner, Domain Therapeutics, will attend the SACHS 23rd annual biotech event in Europe. Dr. Christopher Langmead and colleagues' work on the 5-HT2C receptor as a therapeutic target for substance GPCR Symposium on ''GPCRs as Therapeutic Modalities' Share your project with a 1-minute abstract video Protein and Exendin-P5 Biased Agonist Molecular and structural insights into the 5-HT2C receptor as a therapeutic teams up with addiction treatment maker Indivior to make digital therapeutics for substance use disorders

Celtarys’ cutting-edge fluorescent ligand technology and accelerate the development of GPCR-targeted therapeutics accelerate the adoption of our chemical tools and foster collaborations that turn receptor biology into therapeutic

This week's highlights: Kudos to our partner, GPCR Therapeutics, for partnering with Bridge Biotherapeutics acids conjugation with [Cp*Rh(H2O)3]2+ by using the meta-dynamics/FMO3 approach Industry News GPCR Therapeutics - Providing the next generation of high-impact medicines Structure Therapeutics Provides Comprehensive Study Neurocrine opening two Phase 1 trials in oral Parkinson’s therapies Bearing Fruit: Deep Apple Therapeutics Launches to Screen AI-Generated Virtual Libraries AbbVie to Acquire Cerevel Therapeutics in Transformative

Eosinophilic inflammation is a hallmark of refractory chronic rhinosinusitis (CRS) and considered a major therapeutic (ECRS) via macrophage IL‐1β overproduction, thereby suggesting autophagy regulation as a potential therapeutic We sought to investigate the therapeutic potential of autophagy‐enhancing agent, trehalose, or related Methods We investigated the therapeutic effects of trehalose and saccharin on macrophage IL‐1β production